GERARD MICHEL

Chief Executive Officer

Q

GERARD MICHEL
Chief Executive Officer

Gerard Michel
Mr. Michel has over 30 years of experience in the pharmaceutical and medical technology industries across multiple functional areas.

Prior to joining the Company, Mr. Michel was Chief Financial Officer of Vericel Corp., a biopharmaceutical company, since June 2014 where he was a key member of the management team which integrated a transformative acquisition and revised the company’s business model from a research focused company to a fully integrated, profitable commercial business. Mr. Michel also served as Chief Financial Officer and Vice President, Corporate Development of Biodel Inc., a specialty biopharmaceutical company focused on the treatment of diabetes, from November 2007 to May 2014, and Chief Financial Officer and Vice President of Corporate Development of NPS Pharmaceuticals Inc., a biopharmaceutical company focused on treatment options for patients with gastrointestinal and endocrine disorders, from August 2002 to November 2007. Prior to that, Mr. Michel was a Principal at Booz Allen Hamilton Inc. and also held a variety of commercial roles at both Lederle Labs and Wyeth Labs. Mr. Michel holds an M.S. in Microbiology from the University of Rochester School of Medicine, an M.B.A. from the Simon School of Business, and a B.S. in both Biology and Geology from the University of Rochester.

JOHN PURPURA

Chief Operating Officer

Q

JOHN PURPURA
Chief Operating Officer

John Purpura
John joined Delcath as Executive Vice President for Regulatory Affairs and Quality Assurance in November 2009, and was promoted to Executive Vice President – Global Head of Operations in July 2016. He also served as Interim Chief Executive Officer of the Company from June 1, 2020 to October 1, 2020.

Prior to joining the Company, he was with Bracco Diagnostics (formerly E-Z-EM,Inc.) as Vice President and then Executive Director of International Regulatory Affairs from 2007 to 2008 and Head of Regulatory Affairs for North America and Latin America from 2008 to 2009. Prior to E-Z-EM, Inc., Mr. Purpura had an 11-year career with Sanofi-Aventis, ultimately serving as Associate Vice President for Regulatory CMC from 2005 to 2007. From 1985 to 1995, he had various quality and regulatory management roles with Bolar Pharmaceuticals, Luitpold Pharmaceuticals and Eon Labs Manufacturing. He earned his M.S. in Management & Policy and B.S. degrees in Chemistry and Biology at the State University of New York at Stony Brook.

VOJISLAV “VOJO” VUKOVIC, MD, MSc, PhD

Chief Medical Officer

Q

VOJISLAV “VOJO” VUKOVIC, MD, MSc, PhD
Chief Medical Officer

Dr. Vukovic is an experienced drug development executive with a distinguished career in cancer research and global clinical development. His experience spans early- to late-stage clinical development projects across multiple anticancer modalities and tumor types and global medical affairs programs supporting several commercial oncology drugs. He has held the position of Senior Vice President and Chief Medical Officer at Aileron Therapeutics, Taiho Oncology Inc, and Synta Pharmaceuticals Inc, overseeing various facets of clinical development, medical affairs, and corporate strategy.

Dr. Vukovic earned his MD from the University of Sarajevo in Bosnia and Herzegovina and an MSc in radiation biology and a PhD in tumor biology from the University of Toronto in Canada. His work has been published in several high-impact scientific journals, and he is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the American Society of Hematology, and the European Society for Medical Oncology.

JOHNNY JOHN, MD

Senior Vice President Clinical Development & Medical Affairs

Q

JOHNNY JOHN, MD
Senior Vice President Clinical Development & Medical Affairs


Dr. John has worked in oncology drug development and clinical trials for over 15 years.

Prior to joining Delcath he worked in Clinical Trial Operations at InVentiv Health. Among the clinical programs he worked on there were the trials that resulted in the FDA approval of Ipilimumab. Prior to InVentiv Health, Dr. John spent over 11 years in clinical practice. He received his medical degree from Mangalore University, India and postgraduate training at the University of Illinois.

KEVIN MUIR

General Manager
Interventional Oncology

Q

KEVIN MUIR
General Manager Interventional Oncology


Mr. Muir joins Delcath Systems with 20 years of sales and marketing experience in the biotherapeutics and medical technology industries.

Before joining Delcath, Mr. Muir was Director of U.S. Sales for the Interventional Oncology business unit at BTG, where he played a key role in the success of TheraSphere™ (custom ordered micro-embolic 90Y radiation radio isotope-therapy). Prior to that he was Director of Sales at ClearFlow Inc. and Aragon Surgical. Mr. Muir also held leadership sales roles at Kensey Nash Corporation, Kyphon, and Genzyme Biosurgery. Prior to his career in industry, Mr. Muir served as a Field Artillery officer in the U.S. Army. He completed his BS in Management Systems Engineering at the United States Military Academy at West Point where he was a member of the West Point Cadets Football Team.

DAVID HOFFMAN

General Counsel, Corporate Secretary & Chief Compliance Officer

Q

DAVID HOFFMAN
General Counsel, Corporate Secretary
& Chief Compliance Officer


David brings over 20 years of experience advising biotechnology companies with a focus on the commercialization of therapies.

Most recently, he served as Associate General Counsel and Chief Compliance Officer at Vericel Corporation, where he was responsible for legal and compliance matters and supported the launch and growth of products in the advanced cell therapy and biologics space. His background and counsel will be a crucial asset as we continue to progress on our mission to commercialize new therapies to treat cancers of the liver.

SANDRA PENNELL

Senior Vice President of Finance

Q

SANDRA PENNELL
Senior Vice President of Finance


Sandra has 20+ plus years in a variety of financial areas including complete oversight of the Finance and Accounting function specializing in SEC reporting, equity raises, FP&A, all accounting functions in addition to treasury experience related to debt financings and internal investment decisions. She previously held the position of VP, Finance at Invivyd, Inc. and prior to that she was the VP & Corporate Controller, Principal Accounting Officer at Vericel Corporation. Sandra earned a Bachelor and Master of Science in Accountancy from University of Illinois at Urbana-Champaign – College of Business.